MAPT and Alzheimer disease: Finally, it bears noting that when using a preclinical AD classification [76], our cohort contains a distribution of putative AD pathology, ranging from 48% without evidence for either CSF Aβ42 or tau to 8% that have presence of both CSF Aβ42 and tau above biomarker cutoffs.